(34.234.223.229)
Users online: 2159    [ij] [ij] [ij] 
Email id
 

Asian Journal of Research in Chemistry
Year : 2020, Volume : 13, Issue : 4
First page : ( 291) Last page : ( 298)
Print ISSN : 0974-4169. Online ISSN : 0974-4150.
Article DOI : 10.5958/0974-4150.2020.00057.7

Sars-cov-2leader-rna-primed transcription and rna-splicing prevention, control and treatment

Farhana Nikhat1, Ansari Thouheed2, Ansari Moid3

1Anjuman-I-Islam's Kalsekar Technical Campus, Plot No. 2 and 3, Sector - 16, Near Thana Naka, Khandagao, New Panvel, Navi Mumbai, Maharashtra, 410206

2Dr. Noor Mohammed Khan General Hospital, Hafr Al-Batein, Saudi Arabia-31991

3Sanofi Group of Pharmacies, Abha, Saudi Arabia

Online published on 16 September, 2020.

Abstract

Many viral and cellular mRNA species contain a leader sequence derived from a distant upstream site on the same gene by a process of RNA splicing. This process usually involves either nuclear functions or self-splicing of RNA molecules. Coronavirus, a cytoplasmic RNA virus, un- folds yet another mechanism of joining RNA, which involves the use of a free leader RNA molecule. This molecule is synthesized and dissociates from the template RNA, and subsequently re-associates with the template RNA at down- stream initiation sites of sub-genomic mRNAs to serve as the primer for transcription. This leader-primed transcriptional process thus generates viral mRNAs with a fused leader sequence. The purpose of the review to aggregate the anti-SARS drugs in the structural proteins from human SARS related coronavirus (SARS-CoV) while knowing little about the functional sites and possible mutations in these proteins. From a probabilistic viewpoint, we can theoretically select the amino acid pairs as potential candidates for anti-SARS drugs.

Top

Keywords

Leader sequence, RNA splicing, SARS-CoV, Anti-SARS drugs.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
451,176,787 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.